PAVmed, Inc. Stock News

NEW YORK , Oct. 15, 2025 /PRNewswire/ --  Lucid Diagnostics Inc.  (Nasdaq: LUCD) ("Lucid" or the "Company"), a commercial-stage, cancer prevention medical diagnostics company and subsidiary of PAVmed Inc. (Nasdaq: PAVM), today announced that it will participate in the 2025 Maxim Growth Summit, being held October 22-23, 2025 in New York City. Dennis McGrath, Lucid's Chief Financial Officer, will...

The Veris Cancer Care Platform to be deployed to enhance personalized cancer care in patients undergoing systemic cancer therapy across OSUCCC – James NEW YORK , Oct. 7, 2025 /PRNewswire/ -- PAVmed Inc. (Nasdaq: PAVM) ("PAVmed" or the "Company") a diversified commercial-stage medical technology company, operating in the medical device, diagnostics, and digital health sectors, and its majority-o...

Scelfo to strengthen and scale Lucid's market access infrastructure ahead of key upcoming reimbursement milestones—including Medicare coverage for EsoGuard—and to accelerate commercial coverage expansion NEW YORK , Sept. 16, 2025 /PRNewswire/ --  Lucid Diagnostics Inc.  (Nasdaq: LUCD) ("Lucid" or the "Company"), a commercial-stage cancer prevention medical diagnostics company and subsidiary of ...

NEW YORK , Sept. 11, 2025 /PRNewswire/ -- Lucid Diagnostics Inc.  (Nasdaq: LUCD) ("Lucid" or the "Company"), a commercial-stage, cancer prevention medical diagnostics company, and subsidiary of PAVmed Inc. (Nasdaq: PAVM), today announced the closing of its previously announced underwritten public offering of 28,750,000 shares of its common stock, including 3,750,000 shares issued pursuant to th...

NEW YORK , Sept. 10, 2025 /PRNewswire/ --  Lucid Diagnostics Inc.  (Nasdaq: LUCD) ("Lucid" or the "Company"), a commercial-stage, cancer prevention medical diagnostics company, and subsidiary of PAVmed Inc. (Nasdaq: PAVM), today announced the pricing of its underwritten public offering of 25,000,000 shares of its common stock at a public offering price of $1.00 per share.

NEW YORK , Sept. 9, 2025 /PRNewswire/ --  Lucid Diagnostics Inc.  (Nasdaq: LUCD) ("Lucid" or the "Company"), a commercial-stage, cancer prevention medical diagnostics company, and subsidiary of PAVmed Inc. (Nasdaq: PAVM), today announced its intention to offer shares of common stock through an underwritten public offering.

Conference call scheduled for Monday, September 8, at 8:30 AM ET to discuss September 4 MolDX Contractor Advisory Committee (CAC) meeting NEW YORK , Sept. 5, 2025 /PRNewswire/ -- Lucid Diagnostics Inc.  (Nasdaq: LUCD) ("Lucid" or the "Company") a commercial-stage, cancer prevention medical diagnostics company, and subsidiary of PAVmed Inc. (Nasdaq: PAVM) ("PAVmed"), today announced it will host...

Fireside chat with Chairman & CEO Lishan Aklog, M.D., scheduled for Friday, September 5, at 8:35 AM EDT NEW YORK , Aug. 27, 2025 /PRNewswire/ -- Lucid Diagnostics Inc.  (Nasdaq: LUCD) ("Lucid" or the "Company") a commercial-stage, cancer prevention medical diagnostics company, and subsidiary of PAVmed Inc. (Nasdaq: PAVM) ("PAVmed"), today announced Lishan Aklog, M.D.